Brief: Adaptive Biotechnologies Launches Enhanced Clonoseq Assay Reports For Patients With Chronic Lymphocytic Leukemia, Now Featuring IGHV Mutation Status
30/09/2021 12:42
Sept 30 (Reuters) - Adaptive Biotechnologies Corp ADPT.O :
* ADAPTIVE BIOTECHNOLOGIES LAUNCHES ENHANCED CLONOSEQ® ASSAY
REPORTS FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA, NOW
FEATURING IGHV MUTATION STATUS
Source text for Eikon: ID:nGNX2pxHC2
Further company coverage: ADPT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adaptive Biotechnologies
See all newsBrief: Adaptive Biotechnologies Corp - Issues $345 Million In 0% Convertible Senior Notes Due 2031 - SEC Filing
U.S. STOCKS ON THE MOVE-Jabil, BWX Technologies, Micron
U.S. STOCKS ON THE MOVE-Jabil, BWX Technologies, Micron
U.S. STOCKS ON THE MOVE-Intel, La-Z-Boy, CME
U.S. STOCKS ON THE MOVE-Intel, La-Z-Boy, AST SpaceMobile